International noninterventional study of acarbose treatment in patients with type 2 diabetes mellitus

Diabetes Research and Clinical Practice

Volumn 92, Issue 1, 2011, Pages 57-64

  Li, Chunlin ^a   Hung, Yi Jen ^b   Qamruddin, Karim ^c   Aziz, Mohamed Fahmy Abdel ^d   Stein, Herbert ^e   Schmidt, Birgit ^e  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^c BAQAI MEDICAL UNIVERSITY   (Pakistan)

^d AIN SHAMS UNIVERSITY   (Egypt)

^e BAYER PHARMA AG   (Germany)

Author keywords

Acarbose; Efficacy; Non interventional study; Safety; Type 2 diabetes

Indexed keywords

ACARBOSE; AMINOTRANSFERASE; BIGUANIDE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN DERIVATIVE; SULFONYLUREA DERIVATIVE;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADD ON THERAPY; ADULT; AMINOTRANSFERASE BLOOD LEVEL; ANGINA PECTORIS; ARTICLE; CHINA; CLINICAL STUDY; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; DIABETIC RETINOPATHY; DIARRHEA; DIET RESTRICTION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLATULENCE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; INDONESIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MIDDLE EAST; MONOTHERAPY; MOROCCO; MULTICENTER STUDY; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONINTERVENTIONAL STUDY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PAKISTAN; PATIENT SATISFACTION; PERIPHERAL VASCULAR DISEASE; PHILIPPINES; POLAND; POSTPRANDIAL STATE; PROSPECTIVE STUDY; SIDE EFFECT; TAIWAN; TREATMENT DURATION;

ACARBOSE; ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 79954621531     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2010.12.033     Document Type: Article

References (36)

1. Adeghate E., Schattner P., Dunn E. An update on the etiology and epidemiology of diabetes mellitus. Ann N Y Acad Sci 2006, 1084:1-29.
2. King H., Aubert R.E., Herman W.H. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998, 21(9):1414-1431.
3. Shaw J.E., Sicree R.A., Zimmet P.Z. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010, 87(1):4-14.
4. Ettaro L., Songer T.J., Zhang P., Engelgau M.M. Cost-of-illness studies in diabetes mellitus. Pharmacoeconomics 2004, 22(3):149-164.
5. Hanefeld M., Fischer S., Julius U., Schulze J., Schwanebeck U., Schmechel H., et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the diabetes intervention study, 11-year follow-up. Diabetologia 1996, 39(12):1577-1583.
6. Ceriello A., Hanefeld M., Leiter L., Monnier L., Moses A., Owens D., et al. Postprandial glucose regulation and diabetic complications. Arch Intern Med 2004, 164(19):2090-2095.
7. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-h diagnostic criteria. Arch Intern Med 2001, 161(3):397-405. DECODE Study Group.
8. Hanefeld M., Schaper F. Acarbose: oral anti-diabetes drug with additional cardiovascular benefits. Expert Rev Cardiovasc Ther 2008, 6(2):153-163.
9. Holman R.R., Cull C.A., Turner R.C. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K prospective diabetes study 44). Diabetes Care 1999, 22(6):960-964.
10. Lebovitz H.E. Alpha-glucosidase inhibitors as agents in the treatment of diabetes. Diabetes Rev. 1998, 6(2):132-145.
11. Van de Laar F.A., Lucassen P.L., Akkermans R.P., Van de Lisdonk E.H., Rutten G.E., Van W.C. Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a cochrane systematic review and meta-analysis. Diabetes Care 2005, 28(1):154-163.
12. Hanefeld M. Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes. Cardiovasc Diabetol 2007, 6:20.
13. Hollander P. Safety profile of acarbose, an alpha-glucosidase inhibitor. Drugs 1992, 44(suppl 3):47-53.
14. Bacchus R.A., Bell J.L., Madkour M., Kilshaw B. The prevalence of diabetes mellitus in male Saudi Arabs. Diabetologia 1982, 23(4):330-332.
15. Tuomilehto J., Korhonen H.J., Kartovaara L., Salomaa V., Stengard J.H., Pitkanen M., et al. Prevalence of diabetes mellitus and impaired glucose tolerance in the middle-aged population of three areas in Finland. Int J Epidemiol 1991, 20(4):1010-1017.
16. Harati H., Hadaegh F., Saadat N., Azizi F. Population-based incidence of type 2 diabetes and its associated risk factors: results from a six-year cohort study in Iran. BMC Public Health 2009, 9:186.
17. Abdella N., Khogali M., al-Ali S., Gumaa K., Bajaj J. Known type 2 diabetes mellitus among the Kuwaiti population. A prevalence study. Acta Diabetol 1996, 33(2):145-149.
18. Wang Y., Mi J., Shan X.Y., Wang Q.J., Ge K.Y. Is China facing an obesity epidemic and the consequences? The trends in obesity and chronic disease in China. Int J Obes (Lond) 2007, 31(1):177-188.
19. Hu D., Sun L., Fu P., Xie J., Lu J., Zhou J., et al. Prevalence and risk factors for type 2 diabetes mellitus in the Chinese adult population: the InterASIA study. Diabetes Res Clin Pract 2009, 84(3):288-295.
20. Bray G.A. Overweight is risking fate Definition, classification, prevalence, and risks. Ann N Y Acad Sci 1987, 499:14-28.
21. Kissebah A.H., Vydelingum N., Murray R., Evans D.J., Hartz A.J., Kalkhoff R.K., et al. Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab 1982, 54(2):254-260.
22. Bouguerra R., Alberti H., Salem L.B., Rayana C.B., Atti J.E., Gaigi S., et al. The global diabetes pandemic: the Tunisian experience. Eur J Clin Nutr 2007, 61(2):160-165.
23. Tseng C.H., Tseng C.P., Chong C.K., Huang T.P., Song Y.M., Chou C.W., et al. Increasing incidence of diagnosed type 2 diabetes in Taiwan: analysis of data from a national cohort. Diabetologia 2006, 49(8):1755-1760.
24. Ajlouni K., Khader Y.S., Batieha A., Ajlouni H., El-Khateeb M. An increase in prevalence of diabetes mellitus in Jordan over 10 years. J Diabetes Complications 2008, 22(5):317-324.
25. Al-Moosa S., Allin S., Jemiai N., Al-Lawati J., Mossialos E. Diabetes and urbanization in the Omani population: an analysis of national survey data. Popul Health Metr 2006, 4:5.
26. Chan J.C., Chan K.W., Ho L.L., Fuh M.M., Horn L.C., Sheaves R., et al. An Asian multicenter clinical trial to assess the efficacy and tolerability of acarbose compared with placebo in type 2 diabetic patients previously treated with diet. Asian Acarbose Study Group. Diabetes Care 1998, 21(7):1058-1061.
27. Hwu C.M., Ho L.T., Fuh M.M., Siu S.C., Sutanegara D., Piliang S., et al. Acarbose improves glycemic control in insulin-treated Asian type 2 diabetic patients: results from a multinational, placebo-controlled study. Diabetes Res Clin Pract 2003, 60(2):111-118.
28. Lam K.S., Tiu S.C., Tsang M.W., Ip T.P., Tam S.C. Acarbose in NIDDM patients with poor control on conventional oral agents. A 24-week placebo-controlled study. Diabetes Care 1998, 21(7):1154-1158.
29. Standards of medical care in diabetes-2010. Diabetes Care 2010, 33(Suppl. 1):S11-S61.
30. Spengler M., Schmitz H., Landen H. Evaluation of the efficacy and tolerability of acarbose in patients with diabetes mellitus: a postmarketing surveillance study. Clin Drug Investig 2005, 25(10):651-659.
31. Mertes G. Safety and efficacy of acarbose in the treatment of type 2 diabetes: data from a 5-year surveillance study. Diabetes Res Clin Pract 2001, 52(3):193-204.
32. Buse J., Hart K., Minasi L. Final results of a large multicenter postmarketing study in patients with type 2 diabetes. Precose resolution of optimal titration to enhance current therapies. Clin Ther 1998, 20(2):257-269. The PROTECT Study.
33. Lin B.J., Wu H.P., Huang H.S., Juang J.H., Sison A., bin Abdul Kadir D.K., et al. Efficacy and tolerability of acarbose in Asian patients with type 2 diabetes inadequately controlled with diet and sulfonylureas. J Diabetes Complications 2003, 17(4):179-185.
34. Pan C.Y., Landen H. Post-marketing surveillance of acarbose treatment in patients with type 2 diabetes mellitus and subjects with impaired glucose tolerance in China. Clin Drug Investig 2007, 27(6):397-405.
35. Hung Y.J., Kuo S.W., Wang C.H., Chang H.Y., Hsieh S.H., Landen H. Postmarketing surveillance of acarbose treatment in Taiwanese patients with type 2 diabetes mellitus. Clin Drug Investig 2006, 26(10):559-565.
36. Laube H. Acarbose: an update of its therapeutic use in diabetes treatment. Clin Drug Investig 2002, 22(3):141-156.